Fudan University

This phase 3 trial is testing a drug called trastuzumab rezetecan, alone or combined with bevacizumab, in 140 women with advanced triple-negative breast cancer that has a specific immune-suppressed pattern. The goal is to see if the combination can delay cancer growth better than…

This study tests whether a combination of two immunotherapy drugs (QL1706), a targeted therapy (bevacizumab), and standard chemotherapy can shrink advanced ovarian cancer before surgery. About 36 women with stage III-IV ovarian cancer will receive the treatment every 3 weeks, the…

This phase II trial compares a new targeted drug, sacituzumab tirumotecan (Sac-TMT), to other antibody-drug conjugates (ADCs) in people with advanced urothelial carcinoma (bladder cancer) that has worsened after prior treatment. The main goal is to see if Sac-TMT causes less seve…

This phase 2 study tests whether the drug hetrombopag can prevent dangerously low platelet counts caused by chemotherapy in breast cancer patients at high risk. About 126 participants will be split into three groups: one getting no preventive drug, one taking hetrombopag continuo…

This study tests whether a new drug, sacituzumab tirumotecan (Sac-TMT), followed by standard chemotherapy (capecitabine), works better than capecitabine alone to keep early-stage, high-risk triple-negative breast cancer from returning. About 420 women without BRCA gene mutations …

This study tests whether giving a daily probiotic mixture for 6 months can improve brain development in preterm infants who received antibiotics after birth. Researchers will enroll 116 babies and measure their developmental scores, gut bacteria changes, and inflammation markers.…

This phase II trial tests an immunotherapy drug called SHR-1701 combined with chemotherapy and radiation for people with unresectable stage III non-small cell lung cancer. The study will enroll 84 participants and compare giving SHR-1701 before or after standard chemoradiation. T…

This Phase 2 trial will enroll 100 young women (ages 18-45) with hormone receptor-positive breast cancer who are already on a 3-month GnRH injection for ovarian suppression. Half will switch to a monthly injection, while the other half stays on the 3-month schedule. The study aim…

This Phase 2 trial tests a new combination of drugs—paclitaxel polymer micelles, trastuzumab, pertuzumab, and adebelimab—against the standard taxane-based regimen for people with advanced HER2-positive breast cancer. About 140 participants will be randomly assigned to one of the …

This phase 3 trial compares three ways of giving the immunotherapy drug toripalimab to people with stage II-IIIA non-small cell lung cancer that can be removed with surgery. Participants will receive toripalimab either before surgery (neoadjuvant), after surgery (adjuvant), or bo…

This phase 3 trial tests whether short-course radiation followed by chemotherapy and an immunotherapy drug (serplulimab) works better than standard long-course chemoradiation for high-risk locally advanced rectal cancer. 612 patients will be randomly assigned to one of the two tr…

This study tests whether an artificial intelligence (AI) model can choose the best combination of targeted drugs for women with HER2-positive breast cancer before surgery. About 280 women with early or locally advanced breast cancer will be randomly assigned to either AI-guided t…

This phase 2 trial tests a new approach for high-risk locally advanced rectal cancer. It combines a shorter course of radiation with chemotherapy (capecitabine and oxaliplatin) and an immunotherapy drug (serplulimab). The study will compare this combo to standard chemoradiation i…

This study tests a combination of three drugs (sintilimab, bevacizumab, and chemotherapy) in people with a rare and aggressive type of stomach cancer that produces a protein called AFP. The goal is to shrink the tumors enough so they can be surgically removed. About 46 adults wit…

This phase 2 trial tests whether adding two immune-boosting drugs (iparomlimab and tovorilimab) to standard chemotherapy and bevacizumab can shrink tumors in people with advanced mesothelioma who have not had prior treatment. About 37 participants will receive the combination eve…

This study tests whether a chemotherapy-free treatment using the targeted drug Dalpiciclib (a CDK4/6 inhibitor) plus hormone therapy works as well as standard chemotherapy for women with small, high-risk, hormone-receptor-positive breast cancer. About 2,288 participants will be r…

This study tests a new drug, QLC5513, alone or with another drug (QL1706) in 60 women with advanced triple-negative breast cancer that has worsened after at least one prior treatment. The goal is to see if these drugs can shrink tumors or slow the cancer's growth. Participants wi…

This study tests different drug combinations given before surgery for locally advanced colorectal cancer. The 134 participants are grouped by their tumor's genetic markers, and each group receives a tailored treatment. The main goal is to see how often the cancer completely disap…

This study tests a new combination of two drugs (becotatug vedotin and pucotenlimab) in 20 adults with advanced penile cancer that has spread and is EGFR-positive. Participants must have failed or be unable to tolerate chemotherapy. The goal is to see if the treatment can shrink …

This study tests a new two-drug combination for people with a certain type of advanced colorectal cancer that has not responded to prior treatments. About 31 adults will receive the drugs to see if tumors shrink and how long that lasts. The goal is to find a better option for lat…

This study tests whether adding surgery and targeted radiation to a new hormone-blocking drug (rezvilutamide) can help men whose prostate cancer has spread to a few spots (oligometastatic). 300 men will be split into three groups: one gets the drug alone, one gets drug plus surge…

This study tests a personalized approach for people with advanced esophageal cancer that cannot be removed by surgery. Doctors will use MRI scans to guide a custom combination of chemotherapy, radiation, and immunotherapy. The goal is to see if this tailored treatment can help ke…

This phase II trial tests whether combining multi-mode thermal therapy (heat treatment) with immunotherapy drugs can help people with HER2-negative breast cancer that has spread to the liver. The study will enroll 30 participants who have already tried at least one prior treatmen…

This small study will test a new device that uses heat to destroy liver tumors in 20 people who cannot have surgery. The main goal is to see if the device is safe and how well it works at shrinking tumors after one month. Researchers will also check how the treatment affects the …

This phase II trial tests two drugs—anlotinib and benmelstobart—as a second-line treatment for people with advanced or metastatic differentiated thyroid cancer that has not responded to first-line therapy. The study will enroll 23 participants and measure how many see their tumor…

This study looks at whether a combination of ribociclib (a targeted drug) and hormone therapy can be as effective as chemotherapy followed by the same combo for people with a common type of early breast cancer (HR+/HER2-). Only patients whose blood tests show no signs of cancer D…

This phase 2 trial tests whether adding branched-chain amino acids (BCAAs) to the drugs lenvatinib and pembrolizumab helps adults with unresectable liver cancer live longer without their cancer worsening. About 234 participants will be randomly assigned to receive the standard tw…

This phase 2 trial tests a new approach for advanced non-small cell lung cancer. It combines chemotherapy and immunotherapy with a special 'high-low mixed-dose' radiotherapy that gives a strong dose to large tumors and a lower dose to smaller ones. The goal is to shrink tumors fa…

This study tests whether a three-drug combination can help people with triple-negative breast cancer whose tumors stopped responding to immunotherapy. About 46 women will receive cromolyn, TQB2102, and panpulimab to see if tumors shrink or stop growing. The goal is to control the…

This study tests whether taking two drugs (imlunestrant and abemaciclib) before surgery can shrink tumors in people with a common type of breast cancer (ER+/HER2-). About 189 women aged 18-75 with early-stage breast cancer will join. The treatment is guided by a marker called Ki6…

This study looks at whether taking leucogen (a drug that raises white blood cell counts) from the start can prevent low white blood cells in people with RET fusion-positive non-small cell lung cancer who are taking pralsetinib. About 25 people who have not had prior treatment wil…

This study tests whether taking the oral drug everolimus after standard chemotherapy can help prevent breast cancer from coming back in people with a specific subtype of triple-negative breast cancer called LAR. The trial will enroll 904 women who have had surgery for early-stage…

This study tests whether giving immunotherapy drugs (nivolumab with or without ipilimumab) or immunotherapy plus radiotherapy before surgery can improve outcomes for people with a specific genetic type of colorectal cancer called MSI-H/dMMR. About 114 participants will be randoml…

This study tests two drugs together—pucotenlimab and becotatug vedotin—for people with advanced cutaneous squamous cell carcinoma that cannot be removed by surgery. The goal is to see if the combination shrinks tumors better than current treatments. About 38 participants will rec…

This study tests whether adding famitinib to SHR-A1811 works better than SHR-A1811 alone for people with a certain type of advanced breast cancer (HR+/HER2-) that no longer responds to CDK4/6 inhibitors. About 248 women aged 18-70 will take part. The goal is to see if the combina…

This study looks at two powerful drugs, sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd), for people with a certain type of advanced breast cancer (HER2-low/TROP2-high). The goal is to find out which drug works best when given first and how to switch if the first sto…

This study tests whether a drug called RC48, combined with chemotherapy, works better than standard treatments for women with advanced HER2-positive breast cancer whose disease has progressed after prior therapy. About 268 participants will be randomly assigned to receive either …

This study tests whether a new drug combination (fruquintinib plus chemotherapy) works better than the current standard (bevacizumab plus chemotherapy) for people with a specific type of advanced colorectal cancer that has a RAS mutation. About 224 adults aged 18 to 75 will be ra…

This phase 2 trial tests whether adding the drug fluzoparib to standard treatment after surgery can help prevent breast cancer from coming back in women with certain inherited gene mutations (HRR). About 334 women with early breast cancer will be randomly assigned to receive eith…

This Phase 2 trial tests whether adding all-trans retinoic acid (a vitamin A derivative) to standard VAC chemotherapy improves outcomes for 106 people aged 14-60 with intermediate-to-high-risk rhabdomyosarcoma, a rare muscle cancer. Participants will receive the drug combo in 21-…

This study tests a combination of two experimental drugs (iparomlimab and tuvoraleimab) plus standard chemotherapy for people with advanced acral or mucosal melanoma, rare and aggressive skin cancers. About 48 adults who have had little or no prior treatment will receive the ther…

This study will follow 1,200 people with extensive-stage small cell lung cancer who are starting treatment with toripalimab plus chemotherapy. Researchers will track how long patients live without their cancer progressing and overall survival, using real-world data from medical r…

This study tests whether adding a traditional Chinese herbal formula (Qiqi Shengmai) to standard care can improve blood flow in the brains of people with moyamoya disease. About 66 adults aged 18 to 80 will receive either the herbal formula or a placebo for a set period. The goal…

This phase II trial tests whether combining a liver-directed procedure (TACE) with an immunotherapy drug (QL1706) before surgery, followed by more immunotherapy after surgery, can help patients with liver cancer that is too large or numerous for standard transplant criteria. The …

This study tests whether a lab test (3D-PTA) that checks which chemotherapy drugs work best on a patient's tumor can improve outcomes after bile duct cancer surgery. About 98 adults with stage II/III bile duct cancer will be randomly assigned to receive either standard capecitabi…

This phase II trial tests a combination of targeted drugs and hormone therapy given before surgery for a specific type of breast cancer (ER-positive, HER2-positive). The goal is to shrink tumors without using standard chemotherapy. The study will enroll 42 women and measure how m…

This study looks at whether actively treating diabetes with drugs like metformin or insulin can help people with metastatic pancreatic cancer live longer when they also receive standard chemotherapy. About 210 adults with both pancreatic cancer and diabetes will be enrolled. The …

This study looks at men with advanced prostate cancer that has spread to other parts of the body. After 6 months of hormone therapy, those whose scans show the cancer is well-controlled may either continue hormone therapy alone or also have their prostate removed. The goal is to …

This phase 2 trial tests a combination of two drugs, envafolimab and lenvatinib, as a first treatment for people with clear cell kidney cancer that has spread to the liver. The study will enroll 30 participants and measure how well the drugs shrink liver tumors. It is not yet rec…

This study tests whether adding the drug disitamab vedotin to standard BCG therapy can help keep high-risk, early-stage bladder cancer from returning. It includes 182 adults whose cancer has been surgically removed but is at high risk of coming back. Participants will receive eit…

This study tests whether a combination of targeted drugs and hormone therapy can replace chemotherapy for people with a specific type of early-stage breast cancer (HR-positive, HER2-positive, no lymph node spread). About 1,500 participants will receive either the standard chemo p…

This phase 2 trial tests a combination of the immunotherapy epalrotokewali, chemotherapy eribulin, targeted therapy anlotinib, and radiotherapy in 46 people with advanced soft tissue sarcoma that has progressed after prior treatment. The goal is to see if this mix can shrink tumo…

This phase II trial tests a combination of two drugs—sacituzumab tirumotecan and furmonertinib—in 45 people with advanced EGFR-mutant non-small cell lung cancer whose first targeted therapy stopped working. The study measures how many patients respond to treatment and how long th…

This phase II trial tests whether a maintenance therapy of trastuzumab plus either pyrotinib or dalpiciclib and endocrine therapy can delay disease progression in people with HER2-positive advanced breast cancer. After an initial treatment with trastuzumab rezetecan, 288 particip…

This phase II trial tests whether a single low dose of radiation to all visible tumors can help immunotherapy work again in people with advanced esophageal cancer that has stopped responding to standard treatment. Thirty-two adults will receive the radiation and continue their or…

This study tests a device that uses both freezing and heating to destroy liver tumors in people with liver cancer or colorectal cancer that has spread to the liver. The goal is to see if this approach improves how long patients live without their cancer growing, and whether it ac…

This study tests whether Huaier granules, a traditional Chinese medicine, can help reduce elevated tumor markers (CEA, CA125, CA153) to normal levels in people with early-stage breast cancer. About 232 participants will take the granules daily for a year alongside standard care. …

This phase 2 trial tests the drug Vebreltinib, taken as a pill for 8 weeks before surgery, in 30 people with stage IIA-IIIB non-small cell lung cancer that has a specific gene change (MET exon 14 skipping). The goal is to see if the drug can shrink tumors enough to improve surger…

This study tests whether a shorter course of hormone therapy (2-3 years) works as well as the standard longer treatment for women with a very low-risk, early-stage breast cancer. About 2,900 women will be randomly assigned to either the shorter or standard treatment. The goal is …

This Phase II trial tests whether adding bevacizumab to trastuzumab deruxtecan (T-DXd) works better than T-DXd alone for people with HER2-low breast cancer that has spread to the brain and cannot be removed by surgery. The study will enroll 140 participants and measure how long t…

This study tests whether a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy works better than a standard immunotherapy-plus-chemo regimen for advanced bile duct cancer. About 104 adults with inoperable or metastatic intrahepatic cholangi…

This Phase II trial tests whether adding neratinib to the standard drug trastuzumab deruxtecan works better than trastuzumab deruxtecan alone for HER2-positive breast cancer that has spread to the brain and cannot be removed by surgery. About 202 women aged 18-70 will be randomly…

This observational study will test an artificial intelligence model that can automatically detect and diagnose kidney tumors and cysts using non-contrast CT scans. Researchers aim to enroll 10,000 patients to build a system that distinguishes between cysts, benign growths, and ma…

This study will develop and test an artificial intelligence system that assesses how clean the bowel is during a colonoscopy. The AI uses video from the colonoscope along with positioning data to give a more accurate cleanliness score. Researchers will analyze 700 colonoscopy vid…

This study tests whether an AI-powered chatbot and smart reminders can encourage more high-risk adults aged 45 to 74 to get a colonoscopy, the best way to detect colorectal cancer early. About 1,680 participants will be split into two groups: one gets usual care, the other also g…

This study tests whether finding and treating a high-risk type of H. pylori bacteria can prevent stomach cancer. Over 4,800 adults aged 40 and older will be assigned to either standard care or a program that screens for risky H. pylori subtypes and offers antibiotic treatment. Re…

This study tests whether an AI chatbot can help women aged 15 to 26 in China feel more confident about getting the HPV vaccine. About 1800 participants will be split into two groups: one gets access to the chatbot, the other does not. Researchers will compare vaccination rates an…

This study tests whether adding Huaier Granule to standard care can reduce proteinuria (excess protein in urine) in breast cancer patients who developed it as a side effect of immunotherapy or anti-angiogenic therapy. About 120 women will be randomly assigned to receive either st…

This study tests whether Huaier Granules, a traditional Chinese medicine, can reduce proteinuria (excess protein in urine) caused by the cancer drugs bevacizumab or anlotinib in lung cancer patients. About 40 adults will be enrolled and followed for 16 weeks to see if the granule…

This study tests whether adding a traditional Chinese herbal pill called Yueju to standard cancer therapy can improve quality of life for people with advanced biliary tract cancer. About 210 adults will be randomly assigned to get either the pill or a placebo, without knowing whi…

This study will give 120 surgery patients one of three anesthetics—propofol, dexmedetomidine, or esketamine—and use high-density EEG to measure brain activity while they are unconscious. The goal is to understand how each drug disrupts brain communication and to find markers that…

This study will look back at medical records of 150 people aged 90 or older who had elective inguinal hernia repair with mesh. Researchers want to see how often serious complications happen and what factors might raise the risk. The goal is to help guide safer surgical decisions …

This study will check if certain immune cells, called precursor exhausted T cells, found in cancer-free lymph nodes can predict whether esophageal cancer completely disappears after immunotherapy. Researchers will study 88 patients before surgery to see if these cells are better …

This observational study will enroll 158 adults with advanced or recurrent esophageal cancer who plan to receive PD-1 inhibitor immunotherapy. Researchers want to see if a high level of a specific immune cell type (precursor exhausted T cells, or Tpex) in cancer-free lymph nodes …

This study looks at whether a simple blood test can help doctors decide the best treatment after surgery for stomach or gastroesophageal junction cancer. About 32 people with stage III or IVA cancer will give blood samples before and after surgery to check for tumor DNA. The goal…

This study looks back at 100 patients who had surgery for a mesh infection after hernia repair. It compares two approaches: removing the entire mesh versus removing only the infected part. The goal is to see which method leads to fewer hernia recurrences and fewer repeat infectio…

This study observes 400 adults with advanced HER2-negative breast cancer who have already received antibody-drug conjugates. Researchers will track how long patients stay cancer-free or alive after starting eribulin-based therapy. The goal is to understand real-world treatment ou…

This study will follow 3000 adults aged 40 and older who are at high risk for stomach cancer. Participants will provide a stool sample and have a normal stomach exam at the start. Researchers will track who develops stomach cancer over 10 years to see if a simple stool test can p…

This study tests whether special PET/MRI scans can predict how well breast cancer treatments work. 300 women will get scans before and after two cycles of therapy. The goal is to find which scan patterns match good or poor responses, helping doctors choose the right treatment for…

This observational study aims to develop a system that combines genetic and clinical data to predict which patients with colorectal cancer that has spread to the liver are at high risk of the cancer coming back after surgery. Researchers will study 200 adults aged 18-75 who have …

This study enrolls 30 people with cancer that has spread (metastasized). Researchers take a sample of the tumor and analyze its RNA to see if they can predict where the cancer originally started. No treatment is given; the goal is to see how accurate the RNA test is at identifyin…

This study looks at whether stopping GLP-1 receptor agonists (like Ozempic or Wegovy) for two weeks before an upper endoscopy lowers the chance of food staying in the stomach. Researchers will review medical records from over 16,000 people to compare those who paused the drug wit…

This study tests whether artificial intelligence (AI) can help more high-risk adults aged 40 to 64 get colonoscopies to screen for colorectal cancer. About 400 participants will be split into two groups: one gets usual care, the other gets AI-assisted support from doctors and nur…

This study tests whether adding a transparent cap to the tip of a colonoscope helps doctors find more polyps (adenomas) in the lower part of the colon during a second look. About 614 adults aged 45 to 75 will be randomly assigned to get either a standard second exam or one with t…

This study will follow 460 diabetes patients who take semaglutide to see if those with nerve damage (neuropathy) are more likely to develop stomach retention, where food stays in the stomach too long. Participants will have a stomach exam to check for retained food or liquid. The…

This study will compare two groups of people having an endoscopy: those who stopped taking semaglutide for one week beforehand, and those who never took it. The goal is to see if stopping the drug reduces leftover food or liquid in the stomach, which can make the procedure safer …